Seroprevalence of mycoplasmosis in broiler, layer, and native chickens in Giza, Egypt

We aimed to investigate Mycoplasma infections among chicken flocks (Ross, Lohmann and native) in Giza, Egypt, using serological tests, including the slide plate agglutination (SPA) test, hemagglutination inhibition (HI) test, and enzyme-linked immunosorbent assay (ELISA). The slide plate agglutination examination, a serological test, indicated the prevalence of Mg and Ms infections of 10.9% and 13.2%, respectively. On 91 SPA test positive serum samples for either Mg or Ms, a passive hemagglutination/hemagglutination inhibition (HI) test was performed. The SPA and HI test findings were found to be comparable. On 90 SPA test positive samples, an ELISA was performed using commercial kits for Mg and Ms serodiagnosis. According to the ELISA data, only 83.33% and 18.88% of SPA test positive samples were confirmed as positive for Ms and Mg infections, respectively. The prevalence increased to 84.44% and 77.77%, respectively, when suspected samples were deemed positive.

A phase II trial of gemcitabine combined with vinorelbine as first-line chemotherapy for metastatic breast cancer

1098

Background: MBC (metastatic breast cancer) is among the leading causes of cancer deaths in women worldwide and in Egypt. Gemcitabine has shown synergy with vinorelbine in preclinical models, and has a toxicity profile that is different from vinorelbine. Methods: This was an open-label, single-arm, non-randomised phase II study in patients with locally advanced or MBC who have been previously treated with one anthracycline with/without taxane, based regimen in the adjuvant/neoadjuvant setting. The primary objective of this study was to assess the efficacy of this combination by determining overall response rate. Secondary endpoints were the assessment of the toxicity of gemcitabine in combination with vinorelbine, as well as the time to disease progression, one-year survival. Results: Of the 74 patients enrolled, 72 patients were evaluable for primary treatment outcome (tumor response rates). Overall response rate was 42%. Four patients (6%) had complete response and 26 patients (36%) had partial response. Nineteen patients (26%) had stable disease. Among the 30 patients who had a response to treatment during the study period, the median time to disease progression was 37 weeks (range 1 -60). Median duration of response was 43 weeks (95% CI 31- unestimated). The probability of surviving one year from the Kaplan-Meier estimate for 12 months is 77% (95% CI 64%-86%). Mean percentage of dose intensity of gemcitabine and vinorelbine received was 86% (SD 13%). Mean number of cycles received was 4.4 (SD 1.8). Grade III-IV neutropenia was reported to be 10%, thrombocytopenia was 1.4%, and febrile neutropenia (with documented infection) was 1.4%. As for the clinical toxicities, the most common grade III-IV toxicities were nausea (24%) and diarrhea and stomatitis (11%). Serious clinical adverse events; 5 (7%) hospitalizations for adverse events mainly due to anemia, febrile neutropenia, septic shock and hepatic failure. There were 2 platelet transfusions and 14 RBC transfusions. Conclusions: With a disease control rate of 68%, gemcitabine/vinorelbine demonstrated to have a promising efficacy and at the same time good tolerability in metastatic breast cancer patients.

[Table: see text]